AbCheck s.r.o. : AbCheck Antibody Discovery Agreement with U3 Pharma

     AbCheck s.r.o. : AbCheck Antibody Discovery Agreement with U3 Pharma

AbCheck s.r.o. / AbCheck Antibody Discovery Agreement with U3 Pharma .
Processed and transmitted by Thomson Reuters ONE. The issuer is solely
responsible for the content of this announcement.

Plzen, Czech Republic; February 18th, 2013: AbCheck s.r.o., the multi antibody
discovery platforms company, announced today that it has entered into a
research collaboration with U3 Pharma GmbH, based in Martinsried, Germany. U3
Pharma is the antibody targeted cancer drug development affiliate of Daiichi
Sankyo Co. Ltd., one of the top 20 leading pharmaceutical companies worldwide.


Under the agreement AbCheck will use its AbSieve discovery platform, which
combines the Company's proprietary phage and yeast display technologies, to
deliver antibodies against an undisclosed number of U3 Pharma targets. U3
Pharma, which has full rights to any antibodies selected, will pay AbCheck
discovery fees and milestone payments. Other financial and deal terms are not
disclosed.

"The selection of AbCheck by U3 Pharma is very important to us," said Dr.
Volker Lang, Managing Director of AbCheck. "Entering into a research
collaboration with the Company, a recognized specialist in innovative
antibody-based therapeutics, further underlines the quality of AbCheck's
antibody discovery technologies and efficient processes that ensure the
delivery of high quality GMP ready antibodies. Furthermore, this deal once
again validates our exceptional business model, which has now been proven
through partnerships with both pharma and biotech companies throughout the US
and Europe."

Dr. Shoji Hirashima, CEO and Managing Director of U3 Pharma said: "AbCheck has
a well-established technology-platform and defined processes for antibody drug
discovery. We believe we will identify good drug candidate antibodies more
efficiently through this collaboration with AbCheck."  

About AbCheck
AbCheck s.r.o. focuses on the discovery and/or optimization of human
antibodies for partner companies. AbSieve, the combined phage and yeast
display platforms, is used to develop antibodies in all antibody formats
including full length IgGs as well as customer specific and novel antibody
formats. AbAccel, a proprietary algorithm for affinity maturation and
optimization, is combined with Phage or Yeast Display and addresses affinity
maturation, developability and stability optimization of antibodies in just
one step. Antibodies generated by AbCheck's AbSieve and AbAccel platforms have
extremely high specificities and affinities, they are "GMP ready" and have
improved drugability. Furthermore, the use of Yeast display allows the
screening in the final antibody drug format. AbCheck has entered into several
partnerships and is recognized for its expertise in antibody discovery
throughout the US and Europe.

About U3 Pharma
U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in
targeted cancer drug development. Established in July 2001, the company has
produced a pipeline of novel targeted therapeutics based on the
ground-breaking discoveries made by its founder - Professor Axel Ullrich.

Since May 2008, U3 Pharma has been an affiliate ofDaiichi Sankyo Co. Ltd.,
one of the top 20 leading pharmaceutical companies worldwide and No. 3 in
Japan. Being part of this global environment, U3 Pharma is striving to provide
patients around the world with innovative antibody-based therapeutics.

About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative
pharmaceutical products to address the diversified, unmet medical needs of
patients in both mature and emerging markets. While maintaining its portfolio
of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial
infections, the Group is engaged in the development of treatments for
thrombotic disorders and focused on the discovery of novel oncology and
cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has
created a "Hybrid Business Model," which will respond to market and customer
diversity and optimize growth opportunities across the value chain. For more
information, please visit www.daiichisankyo.com.

For further information:

AbCheck s.r.o.            MC Services AG
Dr. Volker Lang           Anne Hennecke
Managing Director         Managing Partner

Phone: +420 378 051500    Phone: +49 89 210 228 18
Fax: +420 378 051506      Fax: +49 89 210 228 88
Email: V.Lang@abcheck.eu  Email: anne.hennecke@mc-services.eu

Press Release (PDF)

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: AbCheck s.r.o. via Thomson Reuters ONE
HUG#1678934

--- End of Message ---

AbCheck s.r.o.
Vedeckotechnicky park Plzen Plzen Czech Republic
 
Press spacebar to pause and continue. Press esc to stop.